VJOncology is committed to improving our service to you

ELCC 2019 | NSCLC: a treatment landscape in flux in the checkpoint inhibitor era

VJOncology is committed to improving our service to you

Martin Reck

The treatment landscape of non-small cell lung cancer (NSCLC) is in a state of flux, with novel immuno-oncology agents and combinations at the forefront. Here, Martin Reck, MD, PhD, from Lung Clinic Grosshansdorf, Grosshansdorf, Germany, gives his insight into this changing field and the future considerations. This interview took place at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter